NCT06616987View on ClinicalTrials.gov

Prevention of Sacituzumab Govitecan-related Neutropenia in Patients With Metastatic Triple Negative Breast Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 3, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

December 31, 2027

Conditions
Breast Cancer Metastatic
Interventions
DRUG

Sacituzumab Govitecan with pegfilgrastim

"▪ Sacituzumab Govitecan group~\- Sacituzumab Govitecan 10mg/kg IV on CnD1 and D8 + Pegfilgrastim 6mg SC QD on CnD9"

Trial Locations (1)

06351

RECRUITING

Samsung Medical Center, Seoul

All Listed Sponsors
lead

Yeon Hee Park

OTHER